NPY and metabolic dysfunction-associated steatotic liver disease: Also, another interesting antagonist mechanism to treat NAFLD is found in the NPY, the expression of which correlates with the liver mass/BW ratio, making it a promising target for therapeutic approaches in adiposity reduction.